ArticleeLife2019
Open access · goldAbstract read
In one paragraph
Article in eLife, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
2.8field-weighted citation impact, top 9% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 23 citations in OpenAlex.
- High-resolution functional mapping of androgen receptor variants.Nature biomedical engineering · 2026Article
- Synergistic targeting strategies for prostate cancer.Nature reviews. Urology · 2025Review
- Targeting mRNA-coding genes in prostate cancer using CRISPR/Cas9 technology with a special focus on androgen receptor signaling.Cell communication and signaling : CCS · 2024Review
- A GREB1-steroid receptor feedforward mechanism governs differential GREB1 action in endometrial function and endometriosis.Nature communications · 2024Article
- Androgen Receptor-Interacting Proteins in Prostate Cancer Development and Therapy Resistance.The American journal of pathology · 2024Review
- A MYCN-independent mechanism mediating secretome reprogramming and metastasis inScience advances · 2023Article
- Androgen receptor activity in prostate cancer dictates efficacy of bipolar androgen therapy through MYC.The Journal of clinical investigation · 2022Article
- Allosteric interactions prime androgen receptor dimerization and activation.Molecular cell · 2022Article
- A genome-scale CRISPR screen reveals PRMT1 as a critical regulator of androgen receptor signaling in prostate cancer.Cell reports · 2022Article
- Overexpression of BQ323636.1 Modulated AR/IL-8/CXCR1 Axis to Confer Tamoxifen Resistance in ER-Positive Breast Cancer.Life (Basel, Switzerland) · 2022Article
- Comprehensive Analysis of GDF10 Methylation Site-Associated Genes as Prognostic Markers for Endometrial Cancer.Journal of oncology · 2022Article
- MYC-Mediated Ribosomal Gene Expression Sensitizes Enzalutamide-resistant Prostate Cancer Cells to EP300/CREBBP Inhibitors.The American journal of pathology · 2021Article
- GREB1: An evolutionarily conserved protein with a glycosyltransferase domain links ERα glycosylation and stability to cancer.Science advances · 2021Article
- Preclinical Models in Prostate Cancer: Resistance to AR Targeting Therapies in Prostate Cancer.Cancers · 2021Review
- Nursing Genetic Research: New Insights Linking Breast Cancer Genetics and Bone Density.Healthcare (Basel, Switzerland) · 2020Article
- Article
- An Enhancer-Based Analysis Revealed a New Function of Androgen Receptor in Tumor Cell Immune Evasion.Frontiers in genetics · 2020Article
- Article
- Androgen Receptor Signaling in the Development of Castration-Resistant Prostate Cancer.Frontiers in oncology · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Eugine LeeHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, United States.
John WongvipatHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, United States.
Danielle ChoiHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, United States.
Ping WangDepartment of Genetics, Albert Einstein College of Medicine, New York, United States.
Young Sun LeeHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, United States.
Deyou ZhengDepartment of Genetics, Albert Einstein College of Medicine, New York, United States.ORCID 0000-0003-4354-5337
Philip A WatsonHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, United States.
Anuradha GopalanDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, United States.
Charles L SawyersHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, United States.ORCID 0000-0003-4955-6475
Memorial Sloan Kettering Cancer Center · USAlbert Einstein College of Medicine · US
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4MSPORE In Prostate CancerP50CA092629 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Yu Chen, MICHAEL J MORRIS · 2001 to 2026
$63.0MThe MSKCC-UW/Fred Hutch Prostate Cancer Drug Resistance and Sensitivity CenterU54CA224079 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI SAWYERS, CHARLES L. · 2017 to 2021
$6.8MRole of ETS factors in specifying prostate luminal cell identity and androgen receptor dependenceR01CA193837 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI SAWYERS, CHARLES L. · 2015 to 2025
$4.7MUnderstanding Resistance to Next Generation AntiandrogensR01CA155169 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI SAWYERS, CHARLES L. · 2012 to 2022
$3.8MTranslational Research in Oncology Training ProgramT32CA160001 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI SAWYERS, CHARLES L. · 2011 to 2020
$2.0MNCI NIH HHS P30 CA008748NCI NIH HHS P50 CA092629NCI NIH HHS R01 CA155169NCI NIH HHS R01 CA193837NCI NIH HHS T32 CA160001NCI NIH HHS U54 CA224079NIH HHS CA008748NIH HHS CA092629NIH HHS CA155169NIH HHS CA160001NIH HHS CA193837NIH HHS CA224079
Abstract
Genomic amplification of the androgen receptor (
Indexed as
Drug Resistance, NeoplasmAndrogen AntagonistsBenzamidesCell Line, TumorChromatinDNA, NeoplasmHumansMaleNeoplasm ProteinsNitrilesPhenylthiohydantoinProstatic NeoplasmsProtein BindingReceptors, AndrogenTranscription, GeneticAndrogen AntagonistsAR protein, humanBenzamidesChromatinDNA, NeoplasmenzalutamideGREB1 protein, humanNeoplasm ProteinsNitrilesPhenylthiohydantoinReceptors, AndrogenAR coactivatorAR signaling outputcancer biologyenzalutamideGREB1humanintra-tumoral heterogeneity
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.